What is the recommended treatment for stage I extranodal Hodgkin lymphoma?

Treatment for Stage I Extranodal Hodgkin Lymphoma

Stage I extranodal Hodgkin lymphoma should be treated with 2 cycles of ABVD chemotherapy followed by 20 Gy involved-site radiotherapy (ISRT), which represents the standard combined-modality approach for limited-stage disease. 1

Treatment Algorithm

The treatment approach for stage I extranodal HL follows the same principles as limited-stage nodal disease:

Standard Approach (Non-PET Guided)

• 2 cycles of ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine)
• Followed by 20 Gy ISRT to the involved site 1

This regimen was established by the GHSG HD10 trial and represents the least toxic approach with excellent disease control, achieving >90% cure rates in limited-stage disease 1, 2.

Alternative PET-Guided Approach

If you choose to use interim PET scanning after 2 cycles of ABVD 1:

PET-Negative (Deauville score ≤2):

• Add 1 additional cycle of ABVD
• Follow with 20 Gy ISRT

PET-Positive (Deauville score >2):

• Switch to 2 cycles of escalated BEACOPP
• Follow with 30 Gy ISRT

Key Evidence and Rationale

The GHSG HD10 trial definitively showed that 2 cycles of ABVD plus 20 Gy involved-field RT achieved similar freedom from treatment failure and overall survival compared to more intensive regimens (4 cycles or 30 Gy), making it the preferred approach for limited-stage disease 1. Current guidelines recommend ISRT rather than the older involved-field RT, as it uses smaller radiation fields with excellent disease control 1.

Important Caveat About PET-Guided Omission of RT

Do not omit radiotherapy based solely on negative interim PET. Multiple randomized trials (RAPID, H10) consistently demonstrate superior progression-free survival when RT is included, even in PET-negative patients 1. While chemotherapy-alone patients still have good overall prognosis, the PFS advantage with combined-modality treatment is clear.

Clinical Considerations for Extranodal Disease

Primary extranodal HL is rare but follows the same treatment principles as nodal disease 3. The most common extranodal sites are lung, gastrointestinal tract, liver, and bone 3. Case reports confirm excellent outcomes with combined-modality therapy (chemotherapy plus consolidative RT) for extranodal presentations, including unusual sites like the maxillary sinus 4.

Pre-Treatment Requirements 1

• Cardiac evaluation: ECG and echocardiography (due to doxorubicin)
• Pulmonary function tests (due to bleomycin)
• Fertility counseling with consideration of sperm banking or oocyte/ovarian tissue cryopreservation for patients of reproductive age
• Pregnancy test in women of reproductive age
• Hepatitis B, C, and HIV screening

Why This Approach Prioritizes Outcomes

This recommendation balances three critical outcomes:

1. Mortality: The 2 ABVD + 20 Gy ISRT regimen achieves >90% cure rates 1, 2
2. Morbidity: Minimizes chemotherapy cycles and radiation dose/field, reducing acute and late toxicities 1
3. Quality of Life: Preserves fertility potential better than more intensive regimens, reduces cardiac and pulmonary toxicity, and minimizes secondary malignancy risk 1, 5

The combined-modality approach with abbreviated chemotherapy and reduced-dose RT represents decades of clinical trial refinement specifically designed to maintain excellent disease control while minimizing treatment-related harm 1, 2.